母胎医学会声明:预防婴儿呼吸道合胞病毒疾病的临床考虑
呼吸道合胞病毒是5岁以下儿童下呼吸道疾病的主要原因,美国每年约58,000例住院归因于此,≤6个月婴儿病情最重。目前有两种预防产品获批:孕期32 0/7至36 6/7周接种的二价重组呼吸道合胞病毒预融合F蛋白亚单位疫苗,以及用于进入首个呼吸道合胞病毒流行季的≤8月龄婴儿的单克隆抗体尼塞韦单抗。除少数例外,不推荐同时给孕妇接种疫苗和给婴儿使用单克隆抗体,所有婴儿应通过其中一种策略获得保护。
要点
- 孕期32 0/7至36 6/7周可接种二价重组呼吸道合胞病毒预融合F蛋白亚单位疫苗进行季节性预防。
- 尼塞韦单抗可用于进入首个呼吸道合胞病毒流行季的≤8月龄婴儿。
- 除少数例外,不推荐同时给孕妇接种疫苗和给婴儿使用单克隆抗体。
核心结论
- 所有婴儿应通过孕妇接种疫苗或婴儿使用单克隆抗体其中一种策略获得呼吸道合胞病毒保护。
- 除少数例外,不推荐同时给孕妇接种疫苗和给婴儿使用单克隆抗体。
研究设计与样本
- 母胎医学会声明,基于现有安全性和有效性数据、可及性及患者偏好提出临床考虑。
主要发现
- 呼吸道合胞病毒是5岁以下儿童下呼吸道疾病的主要原因,美国每年约58,000例住院归因于此。
- ≤6个月婴儿的发病率和死亡率最严重。
- 辉瑞二价重组呼吸道合胞病毒预融合F蛋白亚单位疫苗在孕期32 0/7至36 6/7周季节性接种。
- 尼塞韦单抗用于进入首个呼吸道合胞病毒流行季的≤8月龄婴儿。
关键数值与推荐
- 孕妇接种疫苗的孕周为32 0/7至36 6/7周。
- 尼塞韦单抗适用于≤8月龄婴儿。
- 除少数例外,不推荐同时使用孕妇疫苗和婴儿单克隆抗体。
临床怎么用
- 母胎医学医生应提供有效且平衡的咨询,帮助患者选择个体化的婴儿呼吸道合胞病毒预防方案。
- 关键考虑包括评估现有安全性和有效性数据、权衡可及性与可获得性、以及患者对孕妇接种疫苗与婴儿单克隆抗体治疗的偏好。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Respiratory syncytial virus is a leading cause of lower respiratory tract illness globally in children aged <5 years. Each year, approximately 58,000 hospitalizations in the United States are attributed to respiratory syncytial virus. Infants aged ≤6 months experience the most severe morbidity and mortality. Until recently, prevention with the monoclonal antibody, palivizumab, was only offered to infants with high-risk conditions, and treatment primarily consisted of supportive care. Currently, 2 products are approved for the prevention of respiratory syncytial virus in infants. These include the Pfizer bivalent recombinant respiratory syncytial virus prefusion F protein subunit vaccine, administered seasonally to the pregnant person between 32 0/7 and 36 6/7 weeks of gestation, and the monoclonal antibody, nirsevimab, administered to infants aged up to 8 months entering their first respiratory syncytial virus season. With few exceptions, administering both the vaccine to the pregnant person and the monoclonal antibody to the infant is not recommended. All infants should be protected against respiratory syncytial virus using one of these strategies. Key considerations for pregnant individuals include examining available safety and efficacy data, weighing accessibility and availability, and patient preferences for maternal vaccination vs infant monoclonal antibody treatment. It will be critical for maternal-fetal medicine physicians to provide effective and balanced counseling to aid patients in deciding on a personalized approach to the prevention of respiratory syncytial virus in their infants.
引用
- Joseph NT, Kuller JA, Louis JM, et al. Society for Maternal-Fetal Medicine Statement: Clinical considerations for the prevention of respiratory syncytial virus disease in infants. Am J Obstet Gynecol. 2023. PMID: 37914061. doi:10.1016/j.ajog.2023.10.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。